Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Publication Date

2-1-2024

PubMed ID:

37982822

Additional Authors:

Additional authors and institutional affiliations

This document is currently not available here.

Share

COinS